Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease.
Costa TEM, Lauar JC, Innecchi MLR, Coelho VA, Moysés RMA, Elias RM.
Int Urol Nephrol. 2022 Sep;54(9):2255-2261. doi: 10.1007/s11255-022-03116-5. Epub 2022 Jan 31.
Drug-induced hyperuricaemia and gout.
Ben Salem C, Slim R, Fathallah N, Hmouda H.
Rheumatology (Oxford). 2017 May 1;56(5):679-688. doi: 10.1093/rheumatology/kew293.
[Secondary hyperuricemia in Down's syndrome].
Okabe H, Mizuguchi M.
Nihon Rinsho. 2003 Jan;61 Suppl 1:318-22.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators.
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
Thiazide and loop diuretics.
Sica DA, Carter B, Cushman W, Hamm L.
J Clin Hypertens (Greenwich). 2011 Sep;13(9):639-43. doi: 10.1111/j.1751-7176.2011.00512.x. Epub 2011 Jul 27.
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A, Taguchi I, Hisauchi I, Yoshida H, Shimabukuro M, Hongo H, Ishikawa T, Kadokami T, Yagi S, Sata M, Node K; DIANA study investigators.
Eur J Med Res. 2023 Jul 17;28(1):238. doi: 10.1186/s40001-023-01208-1.
Hyperuricemia and cardiovascular disease risk.
Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF.
Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1219-25. doi: 10.1586/14779072.2014.957675. Epub 2014 Sep 5.
Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT).
Yokose C, McCormick N, Rai SK, Lu N, Curhan G, Schwarzfuchs D, Shai I, Choi HK.
Diabetes Care. 2020 Nov;43(11):2812-2820. doi: 10.2337/dc20-1002. Epub 2020 Sep 2.
[Physiopathological aspects of secondary hyperuricemia].
Caimi G, Lo Presti R.
Recenti Prog Med. 1991 Nov;82(11):618-28.
